Pulse Biosciences
PLSE
49.09
-0.66
-1.33%
Pulse Biosciences
US · PLSE
#2388 by market cap
Listed 2016
49.09
-0.66
-1.33%
Live - 5344 symbols - heartbeat 150s ago
· 2026-10-08 08:06
Pre-market
48.85
-0.49%
After-hours
49.09
0.00%
- Market cap
- 3.50B
- P/E (TTM)i
- -41.96
- P/Bi
- 35.19
- EPSi
- -1.08
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on PLSE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 16.14% -0.06pp
- Institutions
- 137 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Individual/Insider70.16%
Mutual Fund9.20%
Hedge Fund3.55%
Public Company2.21%
Private Company0.93%
Sovereign Wealth Fund0.15%
Other13.70%
Top holders as of 2026-05-11
Robert Duggan
68.45% · 48.82M sh
BlackRock
2.06% · 1.47M sh
Bank of America Corporation
2.03% · 1.45M sh
Vanguard Capital Management, LLC
1.29% · 919.89K sh
Mahkam Zanganeh
1.22% · 873.47K sh
Portolan Capital Management, LLC
1.06% · 753.33K sh
T. Rowe Price Group, Inc.
1.05% · 748.64K sh
Balyasny Asset Management L.P.
1.01% · 718.10K sh
Genius Inc.
0.88% · 630.11K sh
Citadel Advisors LLC
0.88% · 626.51K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Robert Duggan | Executive Chairperson | 68.45% |
| Mahkam Zanganeh | Independent Director | 1.22% |
| Darrin Uecker | CTO & Director | 0.40% |
| Kevin Danahy | President | 0.06% |
| Paul LaViolette | Independent Co-Chairman of the Board | 0.02% |
| Liane Teplitsky | Chief Operating Officer | 0.01% |
| Richard van den Broek | Independent Director | -- |
| Burke Barrett | President | -- |
| Maria Degois-Sainz | Director | -- |
| Manmeet Soni | Lead Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,025 | $48.80–49.95 |
| 2026-08-27 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,070 | $48.24–48.35 |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +200,000 | -- |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +700,000 | $19.06 |
| 2026-06-10 | Richard van den Broek | Independent Director | Other Derivative Acquisition | +38,423 | $26.89 |
| 2026-06-10 | Robert Duggan | Executive Chairperson | Other Derivative Acquisition | +42,495 | $26.89 |
| 2026-06-10 | Maria Degois-Sainz | Director | Other Derivative Acquisition | +33,793 | $26.89 |
| 2026-06-10 | Mahkam Zanganeh | Independent Director | Other Derivative Acquisition | +44,504 | $26.89 |
| 2026-06-10 | Manmeet Soni | Lead Independent Director | Other Derivative Acquisition | +30,000 | $26.89 |
| 2026-05-10 | Paul LaViolette | Independent Co-Chairman of the Board | Open Market Acquisition | +15,000 | $19.69 |
| 2026-05-10 | Robert Duggan | Executive Chairperson | Open Market Acquisition | +660,233 | $19.69 |
| 2026-03-22 | Darrin Uecker | CTO & Director | Other Derivative Acquisition | +100,000 | -- |
| 2026-02-17 | Kevin Danahy | President | Derivative Exercise and Sale | -5,000 | $1.53–23.64 |
| 2026-02-16 | Kevin Danahy | President | Derivative Exercise and Sale | -60,000 | $1.53–23.63 |
| 2026-02-11 | Kevin Danahy | President | Intent to Sell (Form 144) | -50,000 | $25.25 |
| 2026-02-10 | Kevin Danahy | President | Derivative Exercise and Sale | -60,000 | $1.53–25.20 |
| 2026-02-08 | Kevin Danahy | President | Intent to Sell (Form 144) | -75,000 | $20.75 |
| 2026-02-04 | Maria Degois-Sainz | Director | Other Derivative Acquisition | +53,104 | $13.69–14.72 |
| 2025-10-01 | Kevin Danahy | President | Derivative Exercise and Sale | -4,600 | $1.53–18.53 |
| 2025-09-18 | Kevin Danahy | President | Derivative Exercise and Sale | -20,400 | $1.53–18.49 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:06:51 · For reference only, not investment advice and not tailored to your situation.